Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intratumoral Gemcitabine, Paclitaxel, Carboplatine and Intravenous Nivolumab for Locally Recurrence of Head and Neck Cancers

NCT05835804 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire, Amiens as lead sponsor.

NCT NCT05835804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05835804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intratumoral Gemcitabine, Paclitaxel, Carboplatine and Intravenous Nivolumab for Locally Recurrence of Head and Neck Cancers
Lead sponsor
Centre Hospitalier Universitaire, Amiens
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 30, 2025
Completion date
April 30, 2027
Enrollment
39 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carboplatin, nivolumab, paclitaxel, squamous cell carcinoma of the head and neck